- |||||||||| Prolia (denosumab) / Amgen
Review, Journal: Effect of Antiresorptive Drugs on Osseointegrated Dental Implants: A Systematic Review. (Pubmed Central) - Apr 13, 2024 Physicians and dentists should provide comprehensive information to patients prescribed with antiresorptive drugs, emphasizing the need for an awareness of the risks of MRONJ in the context of osseointegrated implants. A longer term of follow-up is recommended to identify and manage MRONJ around dental implants in an early manner.
- |||||||||| cyclophosphamide / Generic mfg.
Journal: Do we really need cyclophosphamide for lupus nephritis? (Pubmed Central) - Apr 12, 2024 Moreover, in some countries worldwide, patients do not have the privilege of access to biologics or more expensive alternatives. The purpose of this review is to evaluate the contemporary options for initial treatment of nephritis in patients with SLE.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis. (Pubmed Central) - Apr 12, 2024 World Health Organization risk drinking level reductions correlate with Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) AUD diagnosis and criteria, providing further evidence for their use as endpoints in alcohol intervention trials, which has potential implications for broadening the base of AUD treatment. BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.
- |||||||||| Prolia (denosumab) / Amgen, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion: A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma (EUDRACT) - Apr 12, 2024 P1/2, N=72, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Review, Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review. (Pubmed Central) - Apr 11, 2024 Active, not recruiting --> Completed This systematic literature review suggests continued effectiveness of sotrovimab in preventing severe clinical outcomes during BA.2 and BA.5 predominance, both against active/untreated comparators and compared with BA.1 predominance.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Treatment of Frey Syndrome with Botulinum Toxin-A: A Practical Approach from Minor's Test to Injection. (Pubmed Central) - Apr 11, 2024 Additionally, the gold standard of treatment for established Frey's syndrome, botulinum toxin A, is thoroughly described, including its mechanism of action, administration, and potential side effects. Finally, the article underscores the need for further research to enhance our understanding of Frey's syndrome, leading to better diagnostic methods and more tailored treatment options for patients.
- |||||||||| Zejula (niraparib) / GSK, J&J, GSK4524101 / GSK
Trial completion date, Trial primary completion date: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors (clinicaltrials.gov) - Apr 11, 2024 P1/2, N=135, Recruiting, Finally, the article underscores the need for further research to enhance our understanding of Frey's syndrome, leading to better diagnostic methods and more tailored treatment options for patients. Trial completion date: Nov 2025 --> Nov 2029 | Trial primary completion date: Jun 2025 --> Dec 2027
- |||||||||| Altabax (retapamulin) / GSK, Almirall
Journal: Proteins (Pubmed Central) - Apr 11, 2024 Utilizing complementary ribosome profiling strategies to map ORF boundaries, we uncovered dual-encoding ORFs generated by in-frame TIS usage in Salmonella. Besides demonstrating that alternative TIS usage may generate proteoforms with different characteristics, such as differential localization and specialized function, quantitative aspects of conditional retapamulin-assisted ribosome profiling (Ribo-RET) translation initiation maps offer unprecedented insights into the relative utilization of annotated and alternative TIS, enabling the exploration of gene regulatory mechanisms that control TIS usage and, consequently, the translation of N-terminal proteoform pairs.
- |||||||||| botulinum toxin type A (ABBV-950) / AbbVie
Enrollment closed, Adverse events: Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity (clinicaltrials.gov) - Apr 11, 2024 P1/2, N=297, Active, not recruiting, Besides demonstrating that alternative TIS usage may generate proteoforms with different characteristics, such as differential localization and specialized function, quantitative aspects of conditional retapamulin-assisted ribosome profiling (Ribo-RET) translation initiation maps offer unprecedented insights into the relative utilization of annotated and alternative TIS, enabling the exploration of gene regulatory mechanisms that control TIS usage and, consequently, the translation of N-terminal proteoform pairs. Recruiting --> Active, not recruiting
- |||||||||| Prolia (denosumab) / Amgen
Embolization of huge giant cell tumor () - Apr 10, 2024 - Abstract #ECIO2024ECIO_479; However, the drug caused mandibular osteonecrosis, necessitating treatment withdrawal. Due to the location, size, and marked vascularity, embolization was chosen as therapeutic option.
- |||||||||| Saphnelo (anifrolumab) / AstraZeneca
Journal: Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus. (Pubmed Central) - Apr 10, 2024 We report on a 27-year-old Japanese woman with SLE whose alopecia due to chronic DLE was refractory to topical therapy and systemic therapy with oral glucocorticoid, multiple immunosuppressants and belimumab for approximately 8 years after onset, and whose alopecia improved with ANI. ANI can be considered to be an effective treatment option in lupus patients presenting with alopecia due to DLE, even in the chronic refractory stage.
- |||||||||| TLR4 modulator program / GSK
Journal, Stroma: Modulating the Mesenchymal Stromal Cell Microenvironment Alters Exosome RNA Content and Ligament Healing Capacity. (Pubmed Central) - Apr 10, 2024 and CRX-527 (a highly potent synthetic TLR4 agonist that can be used as a vaccine adjuvant or to induce anti-tumor immunity) on exosome molecular cargo, as well as on an in vivo rat ligament injury model to validate exosome potency...Additionally, a link was identified between altered exosomal microRNA levels and expression changes in microRNA targets in ligaments. These findings elucidate the nuanced interplay between MSCs, their exosomes, and tissue regeneration.
- |||||||||| GSK2606414 / GSK, Institute of Cancer Research, Dartmouth College
Journal: Bovine parainfluenza virus type 3 infections induce ER stress-mediated autophagy to facilitate virus replication. (Pubmed Central) - Apr 10, 2024 Moreover, intervention with the PERK inhibitor GSK2606414, ATF6 inhibitor Ceapin-A7, and siRNA technology successfully reverses BPIV3-induced autophagy. In summary, these findings propose that BPIV3 induces ER stress to enhance viral replication through increased autophagy, with the PERK and ATF6 pathways playing a significant role in ER stress-mediated autophagy.
- |||||||||| Benlysta (belimumab) / GSK, ianalumab (VAY736) / MorphoSys, Novartis, Rituxan (rituximab) / Roche
Review, Journal: The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review. (Pubmed Central) - Apr 10, 2024 P2 In addition, ianalumab, a monoclonal antibody with a dual mechanism that targets BAFF-R and deletes peripheral BAFF-R+ B cells, is currently being used for ITP treatment [NCT05885555]. The upcoming results from novel BAFF inhibitors, such as ianalumab, could offer clinicians an additional therapeutic option for treating ITP.
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Rituxan (rituximab) / Roche
Risk of herpes zoster among adults initiating immunosuppressive therapies in the United States () - Apr 9, 2024 - Abstract #AMCP2024AMCP_19; Consideration for HZ vaccination should be made when IS medications are being initiated. These results provide guidance on which drug classes could signal to pro- viders the patients who are appropriate for HZ vaccination upon IS medication initiation.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment open: A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines (clinicaltrials.gov) - Apr 9, 2024 P1/2, N=178, Recruiting, Anti-CGRP antibodies allow the withdrawal of associated preventive treatment in a significant percentage of patients, which supports its effectiveness in real-life conditions. Not yet recruiting --> Recruiting
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion date, Trial primary completion date: A Study of Remote Electrical Neuromodulation for Acute Procedural Pain (clinicaltrials.gov) - Apr 9, 2024 P=N/A, N=80, Recruiting, Not yet recruiting --> Recruiting Trial completion date: Jan 2024 --> Oct 2024 | Trial primary completion date: Jan 2024 --> Oct 2024
- |||||||||| Journal: Diabetic Peripheral Neuropathy: Prevention and Treatment. (Pubmed Central) - Apr 8, 2024
First-line drug therapy for painful diabetic peripheral neuropathy includes duloxetine, gabapentin, amitriptyline, and pregabalin; however, these medications do not restore sensation to affected extremities...Second-line drug therapy includes nortriptyline, imipramine, venlafaxine, carbamazepine, oxcarbazepine, topical lidocaine, and topical capsaicin...Peripheral transcutaneous electrical nerve stimulation is well tolerated and inexpensive, but benefits are modest. Other treatments, such as acupuncture, alpha-lipoic acid, acetyl-L-carnitine, cannabidiol, and onabotulinumtoxinA need further study in patients with diabetic peripheral neuropathy.
- |||||||||| Undisclosed WRN inhibitor / Ideaya Biosci, GSK
Journal, IO biomarker: Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells. (Pubmed Central) - Apr 8, 2024 Efficacy was confirmed in immunotherapy-resistant organoids and patient-derived xenograft (PDX) models. The discovery of potent, selective covalent WRN inhibitors provides proof of concept for synthetic-lethal targeting of WRN in MSI cancer and tools to dissect WRN biology.
- |||||||||| Lynparza (olaparib) / Merck (MSD), AstraZeneca, Zejula (niraparib) / GSK, J&J
Journal, Real-world evidence, BRCA Biomarker, PARP Biomarker, Real-world: Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer. (Pubmed Central) - Apr 8, 2024 Inflammation-related blood data, such as neutrophil count, obtained at the initial pre-treatment visit might serve as potential predictors for prolonged olaparib treatment. While this study offers valuable insights into potential indicators for prolonged olaparib treatment, it underscores the need for more expansive research to strengthen our understanding of PARP inhibitors and optimize treatment strategies in ovarian cancer.
- |||||||||| Review, Journal, Tumor mutational burden, BRCA Biomarker, PD(L)-1 Biomarker, Pan tumor: If it's a target, it's a pan-cancer target: Tissue is not the issue. (Pubmed Central) - Apr 8, 2024
Resistance to biomarker-driven therapeutics is often due to secondary mutations or co-driver gene defects; studies are now addressing the need for customized drug combinations matched to the complex molecular alteration portfolio in each tumor. Future investigation should expand tissue-agnostic therapeutics to encompass both hematologic and solid malignancies and include biomarkers beyond those that are DNA-based.
- |||||||||| Brexafemme (ibrexafungerp) / SCYNEXIS, GSK
Review, Journal: Targeting Fks1 proteins for novel antifungal drug discovery. (Pubmed Central) - Apr 8, 2024 Here, we discuss the role of Fks1 in the survival and adaptation of fungi, guided by insights from evolutionary and structural analyses. Furthermore, we delve into the dynamics of Fks1 modulation with novel antifungal strategies and assess its potential as an antifungal drug target.
|